During the June quarter, the company’s top line also grew at a similar pace as the net profit, recording an 11.6% increase to ₹1,738.4 crore from ₹1,557.6 crore a year ago. The earnings before interest, taxes, depreciation and amortisation (EBITDA) jumped 14% to ₹445.7 crore in the April to June period.
However, the EBITDA margins improved only slightly to 25.6% from 25.1% last year.Separately, the company’s board approved the appointment of Darshan Gada as an Additional (Non-Executive) Director of the company with effect from August 18, 2025. The appointment is subject to the approval of the shareholders.
In June, the Indian arm of the American multinational announced that it would market MSD Pharmaceuticals’ oral anti-diabetes medications in India, including sitagliptin and its combination therapies. Sitagliptin, first introduced in India in 2008, has played a key role in managing type 2 diabetes by lowering HbA1c levels and improving blood sugar control. Despite rising competition from generics, MSD has maintained a strong position in the value segment of this category.
